Atox Bio Revenue and Competitors
Estimated Revenue & Valuation
- Atox Bio's estimated annual revenue is currently $2M per year.
- Atox Bio's estimated revenue per employee is $77,500
- Atox Bio's total funding is $58.4M.
Employee Data
- Atox Bio has 26 Employees.
- Atox Bio grew their employee count by 100% last year.
Atox Bio's People
| Name | Title | Email/Phone |
|---|
Atox Bio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $11.9M | 77 | 7% | N/A | N/A |
#2 | $6221.7M | 40140 | -4% | N/A | N/A |
#3 | $2M | 13 | 0% | N/A | N/A |
#4 | $0.8M | 5 | -55% | N/A | N/A |
#5 | $2.8M | 18 | 6% | $11.1M | N/A |
#6 | $1M | 13 | -41% | N/A | N/A |
#7 | $1.7M | 11 | 0% | N/A | N/A |
#8 | $0.6M | 4 | 0% | N/A | N/A |
#9 | $5.9M | 38 | -5% | N/A | N/A |
#10 | $6.8M | 44 | 7% | N/A | N/A |
What Is Atox Bio?
Atox Bio is a late stage biotechnology company that develops novel immunomodulators to treat critically ill patients. Reltecimod (AB103) , the company?s lead product, is studied in ACCUTE (Reltecimod Clinical Composite endpoint Study in necrotizing soft Tissue InfEctions), a phase 3 clinical trial in patients with Necrotizing Soft Tissue Infections, a rare, life threatening infection for which no therapy currently exists. Reltecimod is also being studied in REAKT (Reltecimod Efficacy for Acute Kidney Injury Trial), a phase 2 study in patients with abdominal sepsis induced Acute Kidney Injury. Reltecimod received Orphan Drug designation from the FDA and EMA and Fast Track designation from the FDA.
keywords:N/A
$58.4M
Total Funding
26
Number of Employees
$2M
Revenue (est)
100%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Atox Bio News
Atox Bio Ltd; Bristol-myers Squibb Co; Five Prime Therapeutics Inc; Johnson & Johnson; Theramab Llc T Cell Specific Surface Glycoprotein Cd28...
The key players operating in the Acute Kidney Injury treatment market include Atox Bio, AM-Pharma, Angion Biomedica, Astellas Pharma,...
Atox Bio, a Ness Ziona, Israel and Chapel Hill, NC –based clinical stage biotechnology company developing novel therapies for critically ill patients, raised $30m in funding. The round was led by Arix Bioscience plc with participation from Adams Street Partners, Asahi Kasei Corporation and addi ...
Israel’s Atox Bio has raised $30 million — the latest in a long line of equity deals — to help push its immune modulators through late-stage clinical trials. The company is working on immune modulators for patients with severe infections and tissue injury. The company ...
Atox Bio, a Ness Ziona, Israel-based developer of therapeutics for severe infections, raised up to $23m in Series E investment. The round was led by SR One with participation by Lundbeckfond Ventures and OrbiMed Israel. The company intends to use the funds to initiate a late stage clinical stu ...
Other Companies in Chapel Hill
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.5M | 27 | -4% | N/A |
#2 | $2.8M | 28 | -24% | N/A |
#3 | $2M | 28 | 40% | N/A |
#4 | $15M | 29 | 7% | N/A |
#5 | $2.9M | 29 | 7% | N/A |